Oncology

News

Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for

News

BMS invests $12m in cancer immunotherapy tie-up with Compuge...

Bristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could boost the effectiveness of its blockbuster cancer immunotherapy Opdivo.<

Events

Partner Content

New Horizon for Treatment of Inherited Retinal Dystrophy

Latest developments and innovations in ocular gene edit

Views & Analysis

Ahead of the curve

Pharma often criticises the NHS for failing to adopt the latest therapies, arguing that NICE’s technology appraisals can drag on and that hospitals often fail to provide the recommended therapies a

News

Celltrion's Rituxan biosimilar gets glowing review ahead of ...

Reviewers from the FDA have given Celltrion’s biosimilar of Roche’s blood cancer blockbuster Rituxan a glowing report ahead of a key meeting of its advisers tomorrow.

News

NICE okays funding for Novartis skin cancer combo

The combination of the Novartis drugs dabrafenib and trametinib for patients with stage 3 skin cancer will be funded by the NHS in England and Wales after a recommendation from cost regulat

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

BMS invests $12m in cancer immunotherapy tie-up with Compuge...

New Horizon for Treatment of Inherited Retinal Dystrophy

Ahead of the curve

Celltrion's Rituxan biosimilar gets glowing review ahead of ...

NICE okays funding for Novartis skin cancer combo

uniQure falls on long-term Huntington's gene therapy data

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks